Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cyproterone acetate 5
Cyproterone 5 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cyproterone acetate 5 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Cyproterone acetate 15 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Cyproterone acetate 25 mg ( DR-2031) | EXPERIMENTAL | 1 tablet daily |
| Placebo | PLACEBO_COMPARATOR | 1 tablet daily |
| Name | Type | Description |
|---|---|---|
| Cyproterone acetate 5 | DRUG | Cyproterone acetate 5 mg |
| Placebo | DRUG | Matching placebo |
| Cyproterone acetate 15 | DRUG | Cyproterone acetate 15 mg |
| Cyproterone acetate 25 | DRUG | Cyproterone acetate 25 mg |
Inclusion Criteria: * Prostate cancer patients who have undergone chemical or surgical castration * History of hot flashes for at least 30 days * Stable prostate cancer therapy for at least 45 days Exclusion Criteria: * Uncontrolled diabetes or severe COPD * History of thromboembolic disease * Li...
Top 20 of 55 competitors
Cyproterone 5 is an investigational small molecule developed by Teva Pharmaceutical Industries Limited (ticker: TEVA). It has been studied in a Phase 2 clinical trial for prostate cancer, specifically to treat hot flashes in prostate cancer patients. It is not yet approved and remains in clinical development.
Cyproterone 5 is being studied for the treatment of hot flashes in prostate cancer patients. The only clinical trial of this drug was conducted in men with prostate cancer. It is an investigational therapy and has not been approved for any indication.
Cyproterone 5 is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker symbol TEVA. Teva is the sponsor of the clinical trial evaluating this drug in prostate cancer patients.
Cyproterone 5 is in Phase 2 clinical development. The single trial for this drug was a Phase 2 study that has been completed. The drug is investigational and has not received FDA approval.
Cyproterone 5 has been evaluated in one clinical trial, NCT00196339, titled "A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients." This completed Phase 2 trial enrolled 315 male participants across the United States and Canada.
Yes, Cyproterone 5 is also known as Cyproterone acetate 5. Both names refer to the same investigational drug developed by Teva Pharmaceutical Industries Limited for prostate cancer.